Epigenome-based cancer risk prediction: rationale, opportunities and challengesMartin Widschwendter, Nora Pashayan, Odette Wegwarth et al.|Nature Reviews Clinical Oncology|2018Cited by 173
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancerM.R. Mirza, Line Bjørge|Gynecologic Oncology|2024Cited by 12
A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patientsKenneth Sooi, David S.P. Tan, Tuan Zea Tan et al.|British Journal of Cancer|2025Cited by 2
PR070/#391 Phase I trial of tilvestamab, a function-blocking antibody inhibiting AXL, in platinum-resistant/refractory high grade serous ovarian cancer (PROC)David S.P. Tan, Line Bjørge, Tuan Zea Tan et al.|International Journal of Gynecological Cancer|2023Cited by 1